Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRTTSE:6034 -0.34%62 EV-to-EBIT is 11.15 as of Sep. 15, 2026, which is 39% below its 10-year median of 18.18. GuruFocus rates TSE:6034 with a GF Score™ of 62/100 and a GF Value™ of 円607.97 (Fairly Valued). The stock has 4 warning signs investors should review. Among 482 Healthcare Providers & Services companies, MRT ranks better than 67.43% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MRT's Enterprise Value is 円1,950 Mil.
MRT's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円175 Mil. Therefore, MRT's EV-to-EBIT for today is 11.15.
The historical rank and industry rank for MRT's EV-to-EBIT or its related term are showing as below:
TSE:6034'
s EV-to-EBIT Range Over the Past 10 Years
Min: -203.46 Med: 18.18 Max: 159.54
Current: 11.15
During the past 12 years, the highest EV-to-EBIT of MRT was 159.54. The lowest was -203.46. And the median was 18.18.
TSE:6034's EV-to-EBIT is ranked better than 67.43% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 14.965
vs TSE:6034: 11.15
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MRT's Enterprise Value for the quarter that ended in Mar. 2026 was 円2,114 Mil.
MRT's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円175 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRT EV-to-EBIT Related Terms
MRT EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MRT's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, MRT's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MRT's EV-to-EBIT falls into.
MRT's current Enterprise Value is 円1,950 Mil.
MRT's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円175 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRT (TSE:6034) has a EV-to-EBIT of 11.15 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MRT and its competitors. This is 39% below median its historical median of 18.18. According to the industry distribution chart, MRT ranks #157 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 32.6%.
Is MRT's EV-to-EBIT too high?
MRT's current EV-to-EBIT of 11.15 is 39% below median its 10-year median of 18.18. The Healthcare Providers & Services industry median EV-to-EBIT is 14.97. MRT's value of 11.15 is 25.5% below this industry median. Based on the distribution chart, MRT ranks #157 out of 482 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MRT has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MRT ranks #157 out of 482 companies for EV-to-EBIT. This puts MRT in the upper half of its industry. The industry median EV-to-EBIT is 14.97. MRT's value of 11.15 is 25.5% below this benchmark. While the company's 10-year median is 18.18 vs. the industry median of 14.97, MRT has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 14.97, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MRT's current EV-to-EBIT of 11.15 is 25.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MRT and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MRT's current EV-to-EBIT is 11.15, which is 39% below median its own 10-year median of 18.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円607.97, compared to a current price of 円592.00 — trading 2.6% below its estimated fair value. The current EV-to-EBIT is 11.15, which is 39% below median its 10-year median of 18.18 and 25.5% below the Healthcare Providers & Services industry median of 14.97. MRT's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MRT (TSE:6034), the current EV-to-EBIT is 11.15 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be undervalued.
The current stock price of 円592.00 is trading 2.6% below its estimated GF Value™ of 円607.97.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
EV-to-EBIT: 11.15 (39% below median its 10-year median of 18.18)
GF Value™: 円607.97 vs. price of 円592.00 (2.6% below fair value)
Industry Position: 25.5% below the Healthcare Providers & Services median (#157 of 482)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
62GF Score
Get the complete analysis for TSE:6034
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
